Takeda, U.S.-Based Amylin To Move Obesity Drug To Final U.S. Trials
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said one of its anti-obesity drugs would move into final-phase U.S. trials later this year